MUC1 and familial pancreatic carcinoma: Some studies have been conducted to assess the use of MVs in prognosis too; in patients with disseminated breast and pancreatic cancer with higher levels of TF (Tissue Factor) and MUC1 (epithelial mucin) in MVs was shown a lower survival rate at 3–9 months followup compared to those with low TF-activity and no MUC1 expression [71].